Albert M L, Darnell J C, Bender A, Francisco L M, Bhardwaj N, Darnell R B
Laboratory of Molecular Neuro-Oncology, Rockefeller University, New York, New York 10021-6399, USA.
Nat Med. 1998 Nov;4(11):1321-4. doi: 10.1038/3315.
Models for immune-mediated tumor regression in mice have defined an essential role for cytotoxic T lymphocytes (CTLs); however, naturally occurring tumor immunity in humans is poorly understood. Patients with paraneoplastic cerebellar degeneration (PCD) provide an opportunity to explore the mechanisms underlying tumor immunity to breast and ovarian cancer. Although tumor immunity and autoimmune neuronal degeneration in PCD correlates with a specific antibody response to the tumor and brain antigen cdr2, this humoral response has not been shown to be pathogenic. Here we present evidence for a specific cellular immune response in PCD patients. We have detected expanded populations of MHC class I-restricted cdr2-specific CTLs in the blood of 3/3 HLA-A2.1+ PCD patients, providing the first description, to our knowledge, of tumor-specific CTLs using primary human cells in a simple recall assay. Cross-presentation of apoptotic cells by dendritic cells also led to a potent CTL response. These results indicate a model whereby immature dendritic cells that engulf apoptotic tumor cells can mature and migrate to draining lymph organs where they could induce a CTL response to tissue-restricted antigens. In PCD, peripheral activation of cdr2-specific CTLs is likely to contribute to the subsequent development of the autoimmune neuronal degeneration.
小鼠免疫介导的肿瘤消退模型已明确细胞毒性T淋巴细胞(CTL)的关键作用;然而,人们对人类自然发生的肿瘤免疫了解甚少。副肿瘤性小脑变性(PCD)患者为探究针对乳腺癌和卵巢癌的肿瘤免疫机制提供了契机。尽管PCD中的肿瘤免疫和自身免疫性神经元变性与针对肿瘤和脑抗原cdr2的特异性抗体反应相关,但尚未证明这种体液反应具有致病性。在此,我们展示了PCD患者存在特异性细胞免疫反应的证据。我们在3名HLA - A2.1 + PCD患者的血液中检测到MHC I类限制性cdr2特异性CTL的扩增群体,据我们所知,这是首次在简单的回忆试验中使用原代人类细胞对肿瘤特异性CTL进行描述。树突状细胞对凋亡细胞的交叉呈递也引发了强烈的CTL反应。这些结果表明了一种模型,即吞噬凋亡肿瘤细胞的未成熟树突状细胞可以成熟并迁移至引流淋巴器官,在那里它们可诱导针对组织限制性抗原的CTL反应。在PCD中,cdr2特异性CTL的外周激活可能促成随后自身免疫性神经元变性的发展。